Pulmovant Completes Enrollment in PHocus Clinical Trial
Pulmovant, a Roivant company, announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease, PH-ILD. Pulmovant completed enrollment of the PHocus clinical trial in under 12 months from first patient dosed, an impressive timeline in clinical development of treatments for PH-ILD. Pulmovant remains on track to report PHocus topline data in the second half of calendar year 2026.
